Antibiotic-resistant bacteria

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Antibiotic, Fidaxomicin

It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Retrieved on: 
Monday, July 12, 2021
Medical specialties, Bacteria, Microbiology, Glycopeptide antibiotics, Environmental microbiology, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Ridinilazole, Gut microbiota, Vancomycin

Ridinilazole is Summit Therapeutics investigational first-in-class drug currently in two pivotal Phase III Ri-CoDIFy clinical trials.

Key Points: 
  • Ridinilazole is Summit Therapeutics investigational first-in-class drug currently in two pivotal Phase III Ri-CoDIFy clinical trials.
  • In a Phase II study, treatment with ridinilazole compared to vancomycin demonstrated a significant sparing effect on the gut microbiome, supporting the production of protective secondary bile acids.
  • This is believed to be the primary mechanism through which ridinilazole elicits its bactericidal action against C. difficile bacteria.
  • The combination of these studies and discoveries provide us with further data in support of the intended efficacy of ridinilazole.

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Pharmaceutical, Health, Health, Life sciences, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Orphan drug

b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.

Key Points: 
  • b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.
  • Seres\xe2\x80\x99 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
  • The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.
  • For more information, please visit www.serestherapeutics.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/\n'

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Clinical medicine, Gastroenterology, Diarrhea, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Feces, C. Diff

\xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.

Key Points: 
  • \xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.
  • infection.\nClostridioides difficile, or C. difficile, infection (CDI) is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration.
  • Accordingly, readers should not place undue reliance on forward-looking statements or information.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.\n'

DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Priority Research Program

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Health sciences, Medicine, Antibiotic-resistant bacteria, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Immunology, Clostridioides difficile, Antimicrobial, Antibiotic, Drug resistance

The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.

Key Points: 
  • The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.
  • By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.
  • Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the world\xe2\x80\x99s first emergencies.
  • It aims to support \xe2\x80\x9cvery ambitious, structuring, long-term (3 to 6 years) research projects favoring interdisciplinarity and contributing to the emergence of synergies between different types of research (fundamental, environmental, clinical, translational), with the goal of stimulating and supporting the emergence of diagnostic, preventive and therapeutic innovations, and ultimately leading to a better use of antibiotics\xe2\x80\x9d.\n'

Global MRSA Testing Market- 3M Co., Abacus Diagnostica Oy, Abbott Laboratories, among others to contribute to the market growth|Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024

Retrieved on: 
Friday, April 2, 2021
Infectious diseases, Bacterial diseases, Healthcare-associated infections, Medical specialties, Antibiotic-resistant bacteria, Methicillin-resistant Staphylococcus aureus, Pathovars, Staphylococcaceae, Market analysis, Articles

The MRSA testing market is poised to grow by $ 518.33 mnduring 2021-2025, progressing at a CAGR ofalmost 12% during the forecast period.

Key Points: 
  • The MRSA testing market is poised to grow by $ 518.33 mnduring 2021-2025, progressing at a CAGR ofalmost 12% during the forecast period.
  • The report on the MRSA testing market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The MRSA testing market analysis includes end-user segment and geography landscape.
  • This study identifies the increasing demand for automation and system integration as one of the prime reasons driving the mrsa testing market growth during the next few years.

Peggy Lillis Foundation releases Care Guide for Patients with C. diff Infections

Retrieved on: 
Friday, March 26, 2021
Diarrhea, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, C. Diff, Microbiology, Infection, Clinical medicine

BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."

Key Points: 
  • BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."
  • The Care Guide provides patients with C. difficile infections and their caregivers wide-ranging information about the disease, its treatment and its long-term impacts in accessible language.
  • The Guide includes easy to understand information on topics C. diff patients frequently ask about, including how C. diff is spread, getting an accurate diagnosis, treatment options for primary and recurrent C. diff, preventing C. diff spread in the home, and socio-emotional impacts of recurrent C. diff.
  • About Peggy Lillis Foundation for C. diff Education & Advocacy
    Founded in response to the April 2010 death of 56-year-old kindergarten teacher, Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) is the leading national organization dedicated to combating C. difficile infections through educating the public, empowering advocates and shaping policy.

Global MRSA Testing Market Report 2021-2025: Focus on POC, Immunodiagnostics, & Molecular Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 23, 2021
Medical devices, Health, Infectious diseases, Bacterial diseases, Healthcare-associated infections, Medical specialties, Antibiotic-resistant bacteria, Methicillin-resistant Staphylococcus aureus, Pathovars, Staphylococcaceae, Clinical medicine

The "Global MRSA Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global MRSA Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The MRSA testing market is poised to grow by $ 518.33 mn during 2021-2025 progressing at a CAGR of 12% during the forecast period.
  • The report on MRSA testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.

Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, March 16, 2021
Bacteria, Medical specialties, Microbiology, Pathogenic bacteria, Gram-negative bacteria, Pseudomonadales, Bacterial diseases, Antibiotic-resistant bacteria, Bacteriophage, Pseudomonas, Staphylococcus aureus, Antimicrobial resistance

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference taking place virtually March 16-18, 2021.

Key Points: 
  • MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference taking place virtually March 16-18, 2021.
  • Management is scheduled to present at 3:10pm ET on Wednesday, March 17.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Peggy Lillis Foundation and Ferring Pharmaceuticals Partner to Support Patients with C. difficile Infection

Retrieved on: 
Thursday, March 11, 2021
Bacteria, Medical specialties, Microbiology, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Firmicutes, Ferring Pharmaceuticals, CDI, Gut flora

Joining forces, PLF and Ferring are eager to continue helping people living with CDI and their loved ones.

Key Points: 
  • Joining forces, PLF and Ferring are eager to continue helping people living with CDI and their loved ones.
  • "We founded PLF ten years ago to fight the infection that took our mother Peggy from us.
  • "We are thrilled to continue our partnership with the Peggy Lillis Foundation, an advocacy group that has done so much for the CDI community," said Dr. Edward Trott, Chief Patient Officer, Ferring Pharmaceuticals.
  • Ferring is committed to exploring the crucial link between the gut microbiome and human health, beginning with the threat of recurrent Clostridioides difficile infections.